ライフサイエンスコーパス: poliovirus vaccine

1 9 to 13.2), when her child received the oral poliovirus vaccine.

2 ular pertussis-hepatitis B virus-inactivated poliovirus vaccine.

3 tate polio eradication using the inactivated poliovirus vaccine.

4 tively modest potential role for inactivated poliovirus vaccine.

5 ks were controlled within 6 months with oral poliovirus vaccine.

6 dule of ages 6 and 10 weeks, along with oral poliovirus vaccine.

7 attenuated substrates for the production of poliovirus vaccines.

8 liomyelitis in recipients of live attenuated poliovirus vaccines.

9 synthesize stable VLPs as future genome-free poliovirus vaccines.

10 (WHO) recommends the discontinuation of oral poliovirus vaccine after eradication of wild poliovirus.

11 1 oral poliovirus vaccine and trivalent oral poliovirus vaccine against type 1 paralytic poliomyeliti

12 stimated efficacy per dose of trivalent oral poliovirus vaccine against type 3 paralytic poliomyeliti

13 say for detecting response to trivalent oral poliovirus vaccine among 224 infants.

14 d regulatory approval for use of inactivated poliovirus vaccine and bivalent OPV in routine immunizat

15 ces in approach observed between inactivated poliovirus vaccine and bivalent OPV.

16 e field efficacies of monovalent type 1 oral poliovirus vaccine and trivalent oral poliovirus vaccine

17 fficacies per dose of monovalent type 1 oral poliovirus vaccine and trivalent oral poliovirus vaccine

18 troduction of newly licensed monovalent oral poliovirus vaccines and new techniques of vaccine delive

19 e (four times as effective as trivalent oral poliovirus vaccine) and the moderate gains in coverage d

20 nonuclear cells (PBMCs) were stimulated with poliovirus vaccine, and memory T cell activation was ana

21 e who received azithromycin or placebo, oral poliovirus vaccine, and provided a blood sample accordin

22 re likely to have received SV40-contaminated poliovirus vaccine as infants, born 1956 through 1962 (6

23 of using primary monkey cells for preparing poliovirus vaccines, because of the possible contaminati

24 s critical for the phased withdrawal of oral poliovirus vaccine, beginning with the type 2 component,

25 cine (tOPV) with bivalent types 1 and 3 oral poliovirus vaccine (bOPV) and global introduction of ina

26 the impact of bivalent (types 1 and 3) oral poliovirus vaccine (bOPV) use in immunization campaigns

27 icipants received IPV, bivalent 1 and 3 oral poliovirus vaccine (bOPV), or no vaccine.

28 Bivalent oral poliovirus vaccine (bOPV; types 1 and 3) is expected to

29 ion (0.66; .44-1.00) when censoring for oral poliovirus vaccine campaigns.

30 fied an analysis censoring follow-up at oral poliovirus vaccine campaigns.

31 Oral poliovirus vaccine can mutate to regain neurovirulence.

32 of making decisions about the timing of oral poliovirus vaccine cessation following global eradicatio

33 Poliovirus vaccine contaminated with live simian virus 4

34 for all countries to maintain high levels of poliovirus vaccine coverage and sensitive surveillance t

35 r increased with 1 exception (13% third dose poliovirus vaccine decrease).

36 (1/40th of a full dose) is unprecedented for poliovirus vaccine delivery.

37 n did not improve the immunogenicity of oral poliovirus vaccine despite reducing biomarkers of enviro

38 earlier) the patient received his last oral poliovirus vaccine dose, approximately 2 years before th

39 children whose mothers had received pre-1963 poliovirus vaccine during pregnancy (22.5% of the childr

40 ing dynamic poliovirus transmission and oral poliovirus vaccine evolution model.

41 A fractional dose of inactivated poliovirus vaccine (fIPV) administered by the intraderma

42 ractional-dose administration of inactivated poliovirus vaccine (fIPV) could increase IPV affordabili

43 type 2, and the introduction of inactivated poliovirus vaccine, for risk mitigation purposes.

44 the response to a supplemental dose of four poliovirus vaccine formulations.

45 he higher efficacy of monovalent type 1 oral poliovirus vaccine (four times as effective as trivalent

46 immunogenicity of serotype-3 monovalent oral poliovirus vaccine given to healthy infants living in 14

47 as recently demonstrated activity in an oral poliovirus vaccine human challenge model.

48 0.1 mL) intradermal doses of the inactivated poliovirus vaccine (ID fIPV) is positively correlated wi

49 or placebo during a randomised trial of oral poliovirus vaccine immunogenicity (CTRI/2014/05/004588).

50 ssess whether antibiotics would improve oral poliovirus vaccine immunogenicity.

51 arned during the introduction of inactivated poliovirus vaccine in 3 countries that would make future

52 (1) introduction of >/=1 dose of inactivated poliovirus vaccine in all 126 countries using oral polio

53 ss the dynamics of genetic reversion of live poliovirus vaccine in humans, we studied molecular evolu

54 t OPV and to introduce 1 dose of inactivated poliovirus vaccine into routine immunization schedules,

55 aptations and infants' uptake of inactivated poliovirus vaccine (IPV) after its introduction into the

56 eptor (PVR) were vaccinated with inactivated poliovirus vaccine (IPV) and evaluated for induced immun

57 es with experience in the use of inactivated poliovirus vaccine (IPV) are important for the global po

58 bOPV) and global introduction of inactivated poliovirus vaccine (IPV) are major steps in the polio en

59 troduction of at least 1 dose of inactivated poliovirus vaccine (IPV) at >/=14 weeks of age through t

60 PV) introduce at least 1 dose of inactivated poliovirus vaccine (IPV) before the global withdrawal of

61 In 2014, 2 studies showed that inactivated poliovirus vaccine (IPV) boosts intestinal immunity in c

62 e ability of fractional doses of inactivated poliovirus vaccine (IPV) delivered intradermally to indu

63 Inactivated poliovirus vaccine (IPV) does not induce an intestinal m

64 ons for a sequential schedule of inactivated poliovirus vaccine (IPV) followed by OPV.

65 Studies assessing inactivated poliovirus vaccine (IPV) immunogenicity in tropical coun

66 The immunogenicity of inactivated poliovirus vaccine (IPV) in developing countries is not

67 oduction of at least one dose of inactivated poliovirus vaccine (IPV) in routine immunisation program

68 ation, countries are introducing inactivated poliovirus vaccine (IPV) into routine vaccination progra

69 Inactivated poliovirus vaccine (IPV) is believed to induce significa

70 Inactivated poliovirus vaccine (IPV) is efficacious against paralyti

71 Inactivated poliovirus vaccine (IPV) is likely to play a large part

72 Inactivated poliovirus vaccine (IPV) is rarely used in tropical deve

73 ) coadministered with monovalent inactivated poliovirus vaccine (IPV) of all 3 serotypes significantl

74 y for developing more-affordable inactivated poliovirus vaccine (IPV) options for low-income countrie

75 by sequential administration of inactivated poliovirus vaccine (IPV) produced in human diploid cells

76 The introduction of the inactivated poliovirus vaccine (IPV) represents a crucial step in th

77 ted that prior immunization with inactivated poliovirus vaccine (IPV) resulted in faster accumulation

78 h vaccination coverage with only inactivated poliovirus vaccine (IPV) since 2005.

79 nue to discuss the role of using inactivated poliovirus vaccine (IPV) to manage the risks of circulat

80 ypes 1 and 3 OPV (bOPV) in 2016, inactivated poliovirus vaccine (IPV) will be the only source of prot

81 ere randomly assigned to receive inactivated-poliovirus vaccine (IPV), administered subcutaneously; t

82 at birth and 3 doses of OPV and inactivated poliovirus vaccine (IPV), and group 3 placebo at birth a

83 ulation partially immunized with inactivated poliovirus vaccine (IPV).

84 s, including the introduction of inactivated poliovirus vaccine (IPV).

85 nses after the administration of inactivated poliovirus vaccine (IPV).

86 PV1, intradermal fractional-dose inactivated poliovirus vaccine (IPV, GlaxoSmithKline), or intramuscu

87 tective properties of serotype 2 inactivated poliovirus vaccines (IPV).

88 ntually need to be replaced with inactivated poliovirus vaccines (IPV).

89 tion of protective properties of inactivated poliovirus vaccines (IPVs) in transgenic (Tg) mice susce

90 Oral poliovirus vaccine is less immunogenic and effective in

91 lanned universal introduction of inactivated poliovirus vaccine is likely to substantially decrease t

92 s where the efficacy of live-attenuated oral poliovirus vaccines is compromised by a high prevalence

93 Beginning in 1955, the creation of poliovirus vaccines led to a stepwise reduction in polio

94 IV/SIV were not detected in these monovalent poliovirus vaccine lots with the reverse transcriptase a

95 rticularly in assays of live attenuated oral poliovirus vaccine lots.

96 n of several doses of monovalent type 1 oral poliovirus vaccine (mOPV1) and bivalent OPV1 and 3 (bOPV

97 the immunogenicity of monovalent type-1 oral poliovirus vaccine (mOPV1) given at shorter than usual i

98 A high-potency monovalent oral type 1 poliovirus vaccine (mOPV1) was developed in 2005 to tack

99 ic polio vaccines, including monovalent oral poliovirus vaccines (mOPVs), are needed for supplemental

100 who had not been vaccinated or had received poliovirus vaccine of inadequate potency.

101 days, followed by serotype-3 monovalent oral poliovirus vaccine on day 14.

102 ber of newborns given the first dose of oral poliovirus vaccine (OPV) according to the RI schedule an

103 radication Initiative plans to stop all oral poliovirus vaccine (OPV) after wild poliovirus eradicati

104 immunogenicity of the first 2 doses of oral poliovirus vaccine (OPV) among unimmunized Mayan infants

105 Interference between oral poliovirus vaccine (OPV) and monovalent (RRV-S1) and tet

106 rofile after routine doses of trivalent oral poliovirus vaccine (OPV) and numerous supplemental doses

107 epitope-specific monoclonal murine anti-oral poliovirus vaccine (OPV) antibodies, and sera from IPV-i

108 he live attenuated Sabin strains in the oral poliovirus vaccine (OPV) are being removed sequentially,

109 f poliovirus used in the manufacture of oral poliovirus vaccine (OPV) are prone to genetic variations

110 fter vaccination with monovalent type 1 oral poliovirus vaccine (OPV) at 6 months and trivalent OPV a

111 del expectations with the experience of oral poliovirus vaccine (OPV) containing serotype 2 (OPV2) ce

112 ldren whose caregivers refuse to accept oral poliovirus vaccine (OPV) contributes to the spread of po

113 The effect of diarrhea on oral poliovirus vaccine (OPV) failure was evaluated using dat

114 immunisation activities with different oral poliovirus vaccine (OPV) formulations, and serotype-spec

115 The attenuated oral poliovirus vaccine (OPV) has many properties favoring it

116 Oral poliovirus vaccine (OPV) has not been used in the United

117 due to past exposure to WPV and use of oral poliovirus vaccine (OPV) in addition to IPV.

118 entail eventual cessation of the use of oral poliovirus vaccine (OPV) in all countries to prevent the

119 the immune response to IPV with that to oral poliovirus vaccine (OPV) in Guatemalan infants.

120 The impaired immunogenicity of oral poliovirus vaccine (OPV) in low-income countries has bee

121 Withdrawal of type 2 oral poliovirus vaccine (OPV) in OPV-using countries required

122 Replication of Sabin strains used in oral poliovirus vaccine (OPV) in the intestines of vaccine re

123 e degree of mucosal immunity induced by oral poliovirus vaccine (OPV) in tropical countries.

124 all 124 countries currently using only oral poliovirus vaccine (OPV) introduce at least 1 dose of in

125 Mucosal immunity induced by oral poliovirus vaccine (OPV) is imperfect and potentially al

126 Intestinal immunity induced by oral poliovirus vaccine (OPV) is imperfect and wanes with tim

127 Trivalent oral poliovirus vaccine (OPV) is known to interfere with mono

128 Each lot of oral poliovirus vaccine (OPV) is tested for neurovirulence in

129 of 34 SIAs used monovalent or bivalent oral poliovirus vaccine (OPV) lacking Sabin 2.

130 ore, throughout, and after the May 2010 oral poliovirus vaccine (OPV) mass immunization campaign.

131 deficiency disorders (PIDD) who receive oral poliovirus vaccine (OPV) may transmit immunodeficiency-a

132 is achieved, the use of live-attenuated oral poliovirus vaccine (OPV) must be discontinued because of

133 irus vaccine in all 126 countries using oral poliovirus vaccine (OPV) only as of 2012, (2) full withd

134 cularly, among adults with a history of oral poliovirus vaccine (OPV) receipt.

135 Oral poliovirus vaccine (OPV) results in an ongoing burden of

136 current national 4-dose live attenuated oral poliovirus vaccine (OPV) schedule with a 4-dose IPV sche

137 sequence identity) to the Sabin type 2 oral poliovirus vaccine (OPV) strain and unrelated (<82% nucl

138 isolates differed from the Sabin type 1 oral poliovirus vaccine (OPV) strain at 1.84% to 3.15% of tot

139 and after a September 2007 switch from oral poliovirus vaccine (OPV) to IPV, using standard coverage

140 xisted between the failure of trivalent oral poliovirus vaccine (OPV) to prevent poliomyelitis and th

141 utation at nucleotide (nt) 472 of Sabin oral poliovirus vaccine (OPV) type 3 is found in conjunction

142 ding lend to the growing consensus that oral poliovirus vaccine (OPV) use should be discontinued as s

143 d in 1979; however, as a consequence of oral poliovirus vaccine (OPV) use that began in 1961, an aver

144 human diploid cells and live attenuated oral poliovirus vaccine (OPV) was evaluated by randomization

145 Oral poliovirus vaccine (OPV) was not available in Samarkand,

146 and carrying-out mopping-up activities, oral poliovirus vaccine (OPV) was selected as the vaccine-of-

147 a polio-free world, the live attenuated oral poliovirus vaccine (OPV) will eventually need to be repl

148 r orally administered vaccines, such as oral poliovirus vaccine (OPV), may also be associated with in

149 The immunogenicity of oral poliovirus vaccine (OPV), particularly the type 3 compon

150 f routine versus mass campaign doses of oral poliovirus vaccine (OPV), serum neutralizing antibodies

151 The live, attenuated oral poliovirus vaccine (OPV), used for more than four decade

152 intestinal mucosal immunity induced by oral poliovirus vaccine (OPV).

153 gnificantly lower mucosal immunity than oral poliovirus vaccine (OPV).

154 y low (7 to 40%) rates of coverage with oral poliovirus vaccine (OPV).

155 y in children previously immunized with oral poliovirus vaccine (OPV).

156 compare the safety profiles of IPV and oral poliovirus vaccine (OPV).

157 is a rare adverse event associated with oral poliovirus vaccine (OPV).

158 poliovirus or those emanating from the oral poliovirus vaccine (OPV).

159 ate circulating live polioviruses using oral poliovirus vaccine (OPV).

160 ate clinical efficacy estimates for the oral poliovirus vaccines (OPV) currently in use.

161 Global withdrawal of serotype-2 oral poliovirus vaccine (OPV2) took place in April 2016.

162 ts had received at least three doses of oral poliovirus vaccine (OPV3).

163 plementary immunisation activities with oral poliovirus vaccines (OPVs) are usually separated by 4 we

164 estimate the clinical effectiveness of oral poliovirus vaccines (OPVs) in Afghanistan and Pakistan b

165 rotection from immunization with inactivated poliovirus vaccine or exposure to OPV virus from routine

166 Before 1963, poliovirus vaccine produced in the United States was con

167 ropositivity was the number of doses of oral poliovirus vaccine received (P < .01), with levels appro

168 be predicted by the number of doses of oral poliovirus vaccine received.

169 eived the third dose of pentavalent and oral poliovirus vaccine, respectively, but only 65% received

170 Repeated administration of oral poliovirus vaccine resulted in progressively shorter per

171 this manufacturer to inactivate SV40 in oral poliovirus vaccine seed stocks based on heat inactivatio

172 th the discovery of SV40 as a contaminant in poliovirus vaccine stocks that were used to inoculate ap

173 erminants of attenuation of the Sabin 2 oral poliovirus vaccine strain (A481 in the 5'-untranslated r

174 3271 to 3637) derived from the Sabin 1 oral poliovirus vaccine strain spanning the 3'-terminal seque

175 n the capsid region of the Sabin type 2 oral poliovirus vaccine strain with corresponding nonpreferre

176 at base 472 in the IRES of the Sabin type 3 poliovirus vaccine strain, known to attenuate neurovirul

177 eceived IPV only, 5 (2.6%) were positive for poliovirus vaccine strains.

178 ype 2 component, introduction of inactivated poliovirus vaccine, strengthening of routine immunizatio

179 Mass vaccination campaigns with the oral poliovirus vaccine targeting children aged <5 years are

180 countries have replaced OPV with inactivated poliovirus vaccine, the VAPP burden is concentrated in l

181 radicate poliomyelitis by administering oral poliovirus vaccine through routine immunization and annu

182 re immunization coverage with trivalent oral poliovirus vaccine (tOPV) has been low.

183 hampered by low responses to trivalent oral poliovirus vaccine (tOPV) in some developing countries.

184 roposed worldwide switch from trivalent oral poliovirus vaccine (tOPV) to bivalent types 1 and 3 OPV

185 Replacement of the trivalent oral poliovirus vaccine (tOPV) with bivalent types 1 and 3 or

186 and 3, compared with that of trivalent oral poliovirus vaccine (tOPV), in South Africa.

187 mutation at nucleotide position 472 of oral poliovirus vaccine type 3 (OPV3) contributes to the deve

188 lve monovalent lots of live, attenuated oral poliovirus vaccine types 1, 2, and 3, which were release

189 dinated cessation of type 2-containting oral poliovirus vaccine use.

190 ich was first discovered as a contaminant of poliovirus vaccines used between 1955 and 1963, remains

191 1 oral poliovirus vaccine and trivalent oral poliovirus vaccine, using the reported number of doses r

192 iously the efficacy of replication-competent poliovirus vaccine vectors.

193 of follow-up, exposure to SV40-contaminated poliovirus vaccine was not associated with significantly

194 CPP children whose mothers received pre-1963 poliovirus vaccine was unlikely to have been due to SV40

195 ed 9-10 months who had already received oral poliovirus vaccine were randomly assigned to receive the

196 The effectiveness of attenuated poliovirus vaccines when given orally to induce both sys

197 after multiple vaccination rounds with oral poliovirus vaccine, which targeted the entire population

198 were previously vaccinated with inactivated poliovirus vaccine, who had preexisting antibodies to th

199 usly, we demonstrated the monitoring of oral poliovirus vaccine with the use of mutant analysis by PC

200 on, the allegations of contamination of oral poliovirus vaccines with human immunodeficiency virus (H